The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Brand Name :
Acylanid
Synonyms :
Acylanid and acetyldigitoxin
Class :
Antiarrhythmic agents and cardiac glycosides
Dosage Forms & StrengthsÂ
Congestive Heart Failure Â
> 1- 2 years: 35 to 60 mcg/kg Â
above 5 years: 20 to 35 mcg/kgÂ
Congestive Heart Failure (CHF)Â
Premature: 20 to 30 mcg/kg
1- 24 months: 35 to 60 mcg/kg
2 - 5 years: 30 to 45 mcg/kg
5 - 10 years: 20 to 35 mcg/kg
Refer to the adult dosing regimenÂ
the combination of carbomycin and acetyldigitoxin may raise the concentration of the drug in the blood
an increase in the serum concentration of acetyldigitoxin may occur when combined with rokitamycin
the potential or intensity of adverse effects can be heightened when flurandrenolide is combined with acetyldigitoxin
the serum levels of acetyldigoxin may be reduced
the serum levels of acetyldigitoxin may be increased
the serum levels of acetyldigitoxin may be increased
the serum levels of acetyldigitoxin may be increased
the risk of cardiac arrhythmia may be increased
the risk of adverse effects may be increased
Action and Spectrum:Â
It inhibits the sodium potassium ATPase pump enhances the sodium levels and calcium levels in myocardial cells.Â
Frequency not definedÂ
atrial fibrillationÂ
dizzinessÂ
Nausea and vomitingÂ
FatigueÂ
Loss of appetiteÂ
HeadacheÂ
FatigueÂ
DiarrheaÂ
Muscle painÂ
Black Box Warning:Â
There is no black box warning associated with acetyldigitoxin.Â
Contraindication/Caution:Â
Contraindication:Â
Hypersensitivity reactionsÂ
TachycardiaÂ
HypokalemiaÂ
Caution:Â
Renal impairmentÂ
Hepatic impairmentÂ
Pregnancy Warnings:Â
Pregnancy Category:Â
Not AvailableÂ
Lactation:Â
The excretion of drug in human breast milk is unknownÂ
Pregnancy Categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the 1st trimester or 2nd trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â
It is used to treat congestive heart failure and works by inhibiting the sodium potassium ATPase pump enhance the sodium levels and calcium levels in myocardial cells.Â
Pharmacodynamics:Â
It reduces the activity of  AV nodes capability which helps in transmiting the electrical impulses.Â
Pharmacokinetics:Â
AbsorptionÂ
Bioavailability is 60%-80%.Â
Distribution:Â
It is widely distributed into the blood stream.Â
MetabolismÂ
It involves in hepatic metabolism.Â
Elimination and Excretion:Â
Excreted renallyÂ
Administration:Â
It is administered orally in the form of capsules and tablets.Â
Patient information leafletÂ
Generic Name: acetyldigitoxinÂ
Pronounced: (uh-SEET-il-di-JI-tox-in)Â
Why do we use acetyldigitoxin?Â
It belongs to the class of cardiac glycoside involves in fast digitalisation to treat congestive heart failure (CHF).Â